American Cancer Society National Prostate Cancer Roundtable

Introducing our final four American Cancer Society #ACSNPCRT steering committee members! Please welcome Senior Scientific Advisor Lorelei Mucci (ACS and Harvard T.H. Chan School of Public Health Steering Committee Members Dr. Walter Rayford (Consortium on Disparities of Urologic Conditions), Dr. Brian Rivers (Morehouse School of Medicine), and Elisabeth Heath (Karmanos Cancer Institute)! We thank all of our volunteer leaders and look forward to working together to eliminate death and suffering from #prostatecancer for all! 

The American Cancer Society invites you to attend a symposium co-hosted with the FDA Oncology Center of Excellence on October 16 in Washington, DC. Join us as we explore strategies to improve the demographic representativeness of oncology clinical trial participation through prospective benchmark setting.   Learn more and register: https://bit.ly/4ew6GQ5 

Meet the ACS NPCRT Steering Committee, part two! We are thrilled to welcome committee members Lannis Hall (Washington University School of Medicine in St. Louis), Ingrid Hall (Centers for Disease Control and Prevention), Phillip Rodgers (University of Michigan Medical School), and Howard Soule (Prostate Cancer Foundation)! We are so grateful for your commitment to improving outcomes across the prostate cancer continuum and for volunteering your time and expertise to lead our efforts. We have one more round of introductions to make--stay tuned!

How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening? Viewpoint out on JAMA Oncology by Sigrid Carlsson & William Oh https://lnkd.in/d8_c2teV Prostate cancer is the most common cancer and second leading cause of cancer death among men in the U.S., yet screening guidelines are inconsistent and confusing compared to clear mammogram guidelines for women. While randomized clinical trials (RCTs) show that prostate-specific antigen (PSA) screening can reduce prostate cancer mortality by 30% over two decades, there is significant variation in recommendations from different guideline groups. The need for unified and clear guidelines on prostate cancer screening is critical to ensure better outcomes and reduce confusion among patients and healthcare providers.

Meet the American Cancer Society NPCRT Steering Committee! A warm welcome to committee members Brian Bragg (ZERO Prostate Cancer), Dr. Peter Choyke (National Cancer Institute (NCI)), Keith Crawford MD, Ph.D (Prostate Health Education Network) and Dr. Ruth Etzioni (Fred Hutch Cancer Center). A huge thank you to these leaders for volunteering their time and effort to chart a path toward better #ProstateCancer outcomes. Stay tuned as we continue to introduce our Steering Committee in the coming days!

The American Cancer Society invites you to join a webinar co-hosted by the ACS Leadership in Oncology Navigation (ACS LION) program and American Society of Clinical Oncology (ASCO) that will dive into the crucial role of #PatientNavigation in oncology. Learn more and register: https://bit.ly/3TyK757 

The American Cancer Society invites you to attend a symposium co-hosted with the FDA Oncology Center of Excellence on October 16 in Washington, DC. Join us as we explore strategies to improve the demographic representativeness of oncology clinical trial participation through prospective benchmark setting.   Learn more and register: https://bit.ly/4ew6GQ5 

William Dahut, MD, the chief scientific officer for the American Cancer Society (ACS), serves as the ACS Chair of the ACS NPCRT. In his role as ACS CSO, he oversees the strategic direction of both intramural and extramural research and manages the organization’s discovery work, including surveillance and health equity science, population science, cancer screening guidelines, and extramural discovery science. Dr. Dahut guides efforts to enhance and focus the ACS’s research program, concentrating priorities where they will be most effective and working with key partners and supporters to further progress. In addition to his keen insights into the tools and resources available at the ACS, Dr. Dahut brings his years of experience as a medical oncologist to his role on the ACS NPCRT.

Dr. Yaw Nyame, MD, MS, MBA brings his patient-centered focus to his role as Vice-Chair for the American Cancer Society NPCRT. Dr. Nyame is a urologic oncologist and surgeon with a research interest in health disparities in urologic cancers, with a focus on using patient-centered approaches to build translational health services, molecular and clinical solutions to health inequities in prostate cancer and other urologic malignancies. His passion for addressing health disparities is shared by the ACS NPCRT, which places emphasis on addressing gaps in prostate cancer health outcomes across racial and ethnic groups.

Meet the inaugural Chair of the American Cancer Society NPCRT, Dr. William Oh, MD! Dr. Oh is a Clinical Professor of Medicine at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai where he cares for patients with genitourinary malignancies, including prostate, renal, bladder and testicular cancers. He was recently the inaugural Chief Medical Officer at the Prostate Cancer Foundation (PCF). Prior to that, he was the Chief Medical Officer at Sema4, a patient-centered health intelligence company. Dr. Oh brings his 25 years of experience as a medical oncologist to his role as Chair, with a keen focus on improving patient outcomes by leveraging the strengths of the ACS Roundtables.